Literature DB >> 6231310

Decreased T lymphocyte migration in patients with malignancy mediated by a suppressor cell population.

D G Hesse, D J Cole, D E Van Epps, R C Williams.   

Abstract

The migration and concentration of lymphocytes at sites of antigenic challenge are an integral part of the expression of delayed cutaneous hypersensitivity, as well as of tumor and graft rejection. In this study, we have analyzed the migration of T lymphocytes from patients with malignancy. We used casein and concanavalin A (Con A)-stimulated mononuclear cell supernatants to stimulate T cell locomotion. Peripheral blood T lymphocytes from 30 patients with established malignancy, 10 patients with indolent malignancy or benign tumor, and 42 normal adult controls were tested. Data are expressed as a migration index (MI), which represents the difference in micrometers between the distance migrated in response to a stimulus and the distance migrated in response to media alone. We observed a marked depression in casein-stimulated T lymphocyte migration in patients with established malignancy (mean MI +/- 1 SD = 17.0 +/- 9 microns) as compared with normal adult controls (mean MI +/- 1 SD = 35.3 +/- 10 microns). Similar results were observed with migration in response to Con A supernatants. T cells from patients with established malignancy had a mean MI of 5.8 +/- 4 microns to Con A supernatants as compared with 24.5 +/- 5 for controls. This depressed migration was apparent both in the distance that cells migrated and in the number of cells that migrated into the membrane. Of 10 patients with indolent malignancy or benign tumor, T cell migration in 8 was not significantly decreased as compared with controls. When we mixed equal concentrations of normal control T lymphocytes with T lymphocytes from patients with cancer and added the mixture directly to the upper compartment of the chemotaxis chamber, the response of the normal T cells to casein was inhibited by an average of 48%. We observed inhibition of this migration of normal cells when we added as little as 10% of patient cells to normal cells. When we mixed normal control T lymphocytes from different donors and added them directly to the upper compartment of the chemotaxis chamber, T lymphocyte migration in response to casein was not significantly altered. If T cells from patients with cancer were cultured overnight, the suppressive effect on lymphocyte locomotion was lost. Our results indicate that there is a population of T lymphocytes in patients with cancer that suppress normal T lymphocyte migration. This suppressor activity may partially explain the subversion of immunosurveillance in established neoplastic states, as well as the defective inflammatory reaction to intradermal injection of antigen observed in many patients with malignancy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6231310      PMCID: PMC425121          DOI: 10.1172/JCI111293

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  Abnormal monocyte chemotactic response in cancer patients.

Authors:  D A Boetcher; E J Leonard
Journal:  J Natl Cancer Inst       Date:  1974-04       Impact factor: 13.506

2.  The delayed hypersensitivity reaction in breast cancer.

Authors:  M M Roberts; W Jones-Williams
Journal:  Br J Surg       Date:  1974-07       Impact factor: 6.939

3.  Clinical immunologic responsiveness in malignant disease. II. In vitro lymphocyte response to phytohemagglutinin and the effect of cytotoxic drugs.

Authors:  M al-Sarraf; S Sardesai; V K Vaitkevicius
Journal:  Oncology       Date:  1972       Impact factor: 2.935

4.  Impaired immunologic reactivity and recurrence following cancer surgery.

Authors:  F R Eilber; D L Morton
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

5.  Delayed hypersensitivity in cancer patients: cutaneous and in vitro lymphocyte response to specific antigens.

Authors:  H S Nelson
Journal:  J Natl Cancer Inst       Date:  1969-05       Impact factor: 13.506

6.  Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells.

Authors:  S Broder; R Humphrey; M Durm; M Blackman; B Meade; C Goldman; W Strober; T Waldmann
Journal:  N Engl J Med       Date:  1975-10-30       Impact factor: 91.245

7.  Suppressor cells in tumor-bearing mice capable of nonspecific blocking of in vitro immunization against transplant antigens.

Authors:  A E Eggers; J R Wunderlich
Journal:  J Immunol       Date:  1975-05       Impact factor: 5.422

8.  Immune response to a syngeneic mammary adenocarcinoma. III. Development of memory and suppressor functions modulating cellular cytotoxicity.

Authors:  O Kuperman; G W Fortner; Z J Lucas
Journal:  J Immunol       Date:  1975-11       Impact factor: 5.422

9.  Lymphocyte reactivity in cancer patients: correlation with tumor histology and clinical stage.

Authors:  W J Catalona; W F Sample; P B Chretien
Journal:  Cancer       Date:  1973-01       Impact factor: 6.860

10.  Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor.

Authors:  S H Zigmond; J G Hirsch
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

View more
  3 in total

Review 1.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

2.  Tumour related inhibition of macrophage chemotaxis in patients with colon cancer.

Authors:  A Hermanowicz; P R Gibson; D P Jewell
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

3.  Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties.

Authors:  S D Wolpe; G Davatelis; B Sherry; B Beutler; D G Hesse; H T Nguyen; L L Moldawer; C F Nathan; S F Lowry; A Cerami
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.